• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.致编辑的信：关于“μ阿片受体配体（S）-美沙酮独特的药效学特性及低滥用倾向”
Mol Psychiatry. 2024 Dec;29(12):3935-3937. doi: 10.1038/s41380-024-02621-6. Epub 2024 May 28.
2
Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'".对《致编辑的信：关于μ阿片受体配体（S）-美沙酮的独特药效学特性及低滥用倾向》的回复
Mol Psychiatry. 2025 Apr;30(4):1708-1709. doi: 10.1038/s41380-024-02864-3. Epub 2024 Dec 6.
3
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone.（S）-美沙酮作为μ-阿片受体配体具有独特的药效学特性和较低的滥用倾向。
Mol Psychiatry. 2024 Mar;29(3):624-632. doi: 10.1038/s41380-023-02353-z. Epub 2023 Dec 25.
4
Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone.μ-阿片受体配体（S）-美沙酮独特的药效学特性及低滥用倾向
Res Sq. 2023 Mar 23:rs.3.rs-2644719. doi: 10.21203/rs.3.rs-2644719/v1.
5
Atomic-Level Characterization of the Methadone-Stabilized Active Conformation of -Opioid Receptor.阿片受体中介定态吗啡稳定的活性构象的原子水平表征
Mol Pharmacol. 2020 Oct;98(4):475-486. doi: 10.1124/mol.119.119339. Epub 2020 Jul 17.
6
Retention rate and illicit opioid use during methadone maintenance interventions: a meta-analysis.美沙酮维持治疗干预期间的留存率及非法阿片类药物使用情况：一项荟萃分析
Drug Alcohol Depend. 2002 Feb 1;65(3):283-90. doi: 10.1016/s0376-8716(01)00171-5.
7
Characterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.美沙酮作为一种β-抑制蛋白偏向性μ-阿片受体激动剂的特性
Mol Pain. 2016 Jun 17;12. doi: 10.1177/1744806916654146. Print 2016.
8
Methadone: applications in pediatric anesthesiology and critical care medicine.美沙酮：在儿科麻醉学和重症监护医学中的应用。
J Anesth. 2021 Feb;35(1):130-141. doi: 10.1007/s00540-020-02887-4. Epub 2021 Jan 12.
9
Opioid-galanin receptor heteromers mediate the dopaminergic effects of opioids.阿片类物质-甘丙肽受体同聚体介导阿片类物质的多巴胺能效应。
J Clin Invest. 2019 Mar 26;129(7):2730-2744. doi: 10.1172/JCI126912.
10
Effects of the delta-opioid agonist SNC80 on the abuse liability of methadone in rhesus monkeys: a behavioral economic analysis.δ-阿片受体激动剂 SNC80 对恒河猴美沙酮滥用倾向的影响：一种行为经济学分析。
Psychopharmacology (Berl). 2011 Aug;216(3):431-9. doi: 10.1007/s00213-011-2235-2. Epub 2011 Mar 3.

引用本文的文献

1
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure ()- and ()-Methadone Metabolites as -Methyl-d-aspartate Receptor Antagonists.对映体纯的（+）-和（-）-美沙酮代谢物作为N-甲基-D-天冬氨酸受体拮抗剂的新合成及药理评价
J Med Chem. 2025 Mar 13;68(5):5455-5470. doi: 10.1021/acs.jmedchem.4c02605. Epub 2025 Feb 25.
2
N-methyl-D-aspartate Receptors and Depression: Linking Psychopharmacology, Pathology and Physiology in a Unifying Hypothesis for the Epigenetic Code of Neural Plasticity.N-甲基-D-天冬氨酸受体与抑郁症：在神经可塑性表观遗传密码的统一假说中联系精神药理学、病理学与生理学
Pharmaceuticals (Basel). 2024 Nov 30;17(12):1618. doi: 10.3390/ph17121618.

本文引用的文献

1
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial.在对标准抗抑郁药反应不足的重度抑郁症患者中，依他佐辛（REL-1017）的疗效和安全性：一项 3 期随机对照试验。
J Clin Psychiatry. 2024 Jun 17;85(3):24m15265. doi: 10.4088/JCP.24m15265.
2
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone.（S）-美沙酮作为μ-阿片受体配体具有独特的药效学特性和较低的滥用倾向。
Mol Psychiatry. 2024 Mar;29(3):624-632. doi: 10.1038/s41380-023-02353-z. Epub 2023 Dec 25.
3
Ketamine and rapid antidepressant action: new treatments and novel synaptic signaling mechanisms.氯胺酮与快速抗抑郁作用：新的治疗方法和新的突触信号转导机制。
Neuropsychopharmacology. 2024 Jan;49(1):41-50. doi: 10.1038/s41386-023-01629-w. Epub 2023 Jul 24.
4
Ketamine in neuropsychiatric disorders: an update.氯胺酮在神经精神疾病中的应用：最新进展。
Neuropsychopharmacology. 2024 Jan;49(1):23-40. doi: 10.1038/s41386-023-01632-1. Epub 2023 Jun 20.
5
The novel uncompetitive NMDA receptor antagonist esmethadone (REL-1017) has no meaningful abuse potential in recreational drug users.新型非竞争性 NMDA 受体拮抗剂依他佐辛（REL-1017）在娱乐性药物使用者中没有明显的滥用潜力。
Transl Psychiatry. 2023 Jun 7;13(1):192. doi: 10.1038/s41398-023-02473-8.
6
Esmethadone (REL-1017) and Other Uncompetitive NMDAR Channel Blockers May Improve Mood Disorders via Modulation of Synaptic Kinase-Mediated Signaling.依美噻吨（REL-1017）和其他非竞争性 NMDA 受体通道阻滞剂可能通过调节突触激酶介导的信号转导改善情绪障碍。
Int J Mol Sci. 2022 Oct 13;23(20):12196. doi: 10.3390/ijms232012196.
7
Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors.REL-1017（盐酸艾司美沙酮）与其他N-甲基-D-天冬氨酸受体通道阻滞剂在人异二聚体N-甲基-D-天冬氨酸受体中的药理学比较特性
Pharmaceuticals (Basel). 2022 Aug 13;15(8):997. doi: 10.3390/ph15080997.
8
REL-1017 (esmethadone; D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats.REL-1017（埃索美拉唑；D-美沙酮）不会引起 Sprague Dawley 大鼠的强化效应、身体依赖和戒断症状。
Sci Rep. 2022 Jul 6;12(1):11389. doi: 10.1038/s41598-022-15055-3.
9
Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial.AXS-05（右美沙芬-安非他酮）治疗重性抑郁障碍的疗效：一项随机、双盲对照试验。
Am J Psychiatry. 2022 Jul;179(7):490-499. doi: 10.1176/appi.ajp.21080800. Epub 2022 May 18.
10
REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial.REL-1017（埃索美拉唑）作为伴发治疗在有主要抑郁混乱的病人：一个阶段 2a 被随机化的双盲的审讯。
Am J Psychiatry. 2022 Feb;179(2):122-131. doi: 10.1176/appi.ajp.2021.21020197. Epub 2021 Dec 22.

Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone'.

作者信息

Pappagallo Marco, Kosten Thomas R, Gorodetzky Charles W, Vocci Frank J, Sapienza Frank L, De Martin Sara, Comai Stefano, Mattarei Andrea, Inturrisi Charles E, Manfredi Paolo L

机构信息

Relmada Therapeutics, Inc., Coral Gables, FL, USA.

Baylor College of Medicine, MD Anderson Cancer Center, University of Houston, Houston, TX, USA.

出版信息

Mol Psychiatry. 2024 Dec;29(12):3935-3937. doi: 10.1038/s41380-024-02621-6. Epub 2024 May 28.

DOI:10.1038/s41380-024-02621-6
PMID:38806691
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609086/
Abstract
摘要